<unk>  (E2/E2-EN) is an injectable combination formulation of estradiol (E2), a short-acting estrogen, and estradiol<unk>  (E2-EN), a long-acting estrogen, which was developed by Boehringer around 1960 for potential medical use but was never marketed. It contained 1 mg E2 and 9 mg E2-EN in oil solution and was intended for administration by intramuscular injection. A single intramuscular injection of E2/E2-EN (1 mg/9 mg) has been found to result in a 10-fold increase in estradiol excretion on the 2nd day post-injection (due to the 1 mg short-acting E2 component). Following this, estradiol excretion remained above the menstrual-cycle average for 10 days post-injection and did not return to baseline until the 24th day post-injection (due to the 9 mg long-acting E2-EN component). E2/E2-EN is similar to estradiol benzoate/estradiol phenylpropionate (brand name Dimenformon Prolongatum), another injectable combination medication of a shorter-acting estrogen (2.5 mg) and a longer-acting estrogen (10 mg). In contrast to E2/E2-EN however, estradiol benzoate/estradiol phenylpropionate was marketed for medical use.
Estradiol/estradiol enanthate
Estradiol benzoate/testosterone propionate
Estradiol valerate/testosterone enanthate
Estradiol benzoate/estradiol phenylpropionate
Estradiol/norethisterone acetate
Estradiol dienantate
Estradiol hemisuccinate/progesterone
Estradiol undecylate/norethisterone enanthate